Jim Cramer says next week’s economic data will drive the markets
CNBC’s Jim Cramer on Thursday said a light earnings calendar next week will concentrate investors’ focus on a…
Jim Cramer on Rocket Lab: “While the Stock’s Cheaper Than SpaceX, It’s Still Pretty Darn Expensive”
Rocket Lab Corporation (NASDAQ:RKLB) was among Jim Cramer’s stock calls on Mad Money, as he highlighted worthy space…
Jim Cramer says SpaceX investors aren’t buying earnings — they’re buying Elon Musk
CNBC’s Jim Cramer said Tuesday that investors flocking to SpaceX are betting on Elon Musk’s ability to create…
Jim Cramer calls elevated CPI ‘artificial inflation’ — what that means for the stock market
The stock market was under pressure again on Wednesday due to an intensification of the war with Iran.…
We’re right-sizing our position in an AI stock after its impressive run
Shortly after the opening bell, we will sell 40 shares of Broadcom at roughly $486. Following the trade,…
We’re starting a position in a chip designer poised to roar in the era of AI agents
We’re initiating a position in Arm Holdings , buying 225 shares at roughly $169. Following Monday’s trade, Jim…
The private equity crunch is not a prelude to the next crisis
We are fixated on two problems: the price of oil and the frailty of our banking system. We…
‘It’s the beginning’ — Cramer warns the weak payroll report shows AI-related job losses are here
CNBC’s Jim Cramer on Friday expressed concern about the surprisingly weak February jobs report . The line that…
We’re dipping into our large cash pile to buy more of this health-care stock
We are buying 90 shares of Cardinal Health at roughly $217. Following the trade, Jim Cramer’s Charitable Trust…
Eli Lilly’s lead in the obesity race gets wider after win against Novo
In the lucrative obesity drug race, there is Eli Lilly — and then there’s everybody else. A pair…
Down Arrow Button Icon
Wall Street’s yearslong bet on AI is facing a severe test on Thursday, as investors might begin to…
Another alliance of health care and AI signals why pharma stocks could be back
Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the…